Finta Bohuslav, Haines David E
Division of Cardiology, William Beaumont Hospital, Northpointe Heart Center, 27901 Woodward Avenue, Suite 300, Berkley, MI 48072-0921, USA.
Cardiol Clin. 2004 Feb;22(1):127-45, ix. doi: 10.1016/s0733-8651(03)00137-1.
The past several years have witnessed a significant growth in the number of institutions offering catheter ablation for atrial fibrillation (AF). This growth has been a result of a better understanding of pathophysiology of AF and use of instruments and approaches that made catheter ablation of AF a safe and an effective alternative to the drug therapy. The procedure increasingly is becoming a therapy of choice for a select group of symptomatic, drug-refractory patients without structural heart disease, and it is being offered to a rapidly widening patient pool. This article reviews the procedural aspects and clinical evidence supporting this wider use of AF ablation. In addition, new techniques and technologies for AF ablation and new avenues of research in this area are explored.
在过去几年中，提供心房颤动（AF）导管消融术的机构数量显著增加。这种增长源于对房颤病理生理学有了更深入的了解，以及使用了使房颤导管消融成为药物治疗的一种安全有效的替代方法的仪器和手段。对于一组特定的无结构性心脏病、有症状且药物治疗无效的患者，该手术越来越成为首选治疗方法，并且其适用的患者群体正在迅速扩大。本文回顾了支持房颤消融术更广泛应用的手术操作方面及临床证据。此外，还探讨了房颤消融的新技术和新工艺以及该领域新的研究途径。
